6min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Dangers of HAVA

This is 18,000 patients in the USU. Like most of these rare diseases, unfortunately, it's awful. Every time I look at one of these, I'm always just like, oh my god, I'm so glad I don't have... It's terrible. The way that this disease is treated today is with a jack inhibitor called jackify from insight. So all the drugs that are being tested for mild fibrosis are all trying to do what Jack-ify does better.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode